Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average PT from Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.25.

A number of equities research analysts have issued reports on TNYA shares. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Canaccord Genuity Group reduced their price target on Tenaya Therapeutics from $18.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, March 13th. Morgan Stanley cut their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 12th. Finally, Chardan Capital reiterated a "buy" rating and set a $9.00 price target on shares of Tenaya Therapeutics in a research report on Friday, May 9th.

Tenaya Therapeutics Price Performance

TNYA stock traded up $0.02 during trading on Monday, reaching $0.69. 2,715,711 shares of the stock traded hands, compared to its average volume of 2,729,017. The business's 50 day moving average price is $0.54 and its 200-day moving average price is $0.78. Tenaya Therapeutics has a 52-week low of $0.36 and a 52-week high of $4.06. The firm has a market capitalization of $111.88 million, a PE ratio of -0.59 and a beta of 3.00.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). On average, equities research analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Several large investors have recently modified their holdings of TNYA. Woodline Partners LP purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $28,000. Commerce Bank acquired a new position in Tenaya Therapeutics during the fourth quarter worth $29,000. Mariner LLC acquired a new position in Tenaya Therapeutics during the fourth quarter worth $30,000. Ground Swell Capital LLC acquired a new position in Tenaya Therapeutics during the fourth quarter worth $32,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at about $45,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.